Brief: Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
24/04/2025 22:53
April 24 (Reuters) - Caribou Biosciences Inc CRBU.O: CARIBOU BIOSCIENCES ANNOUNCES STRATEGIC PIPELINE PRIORITIZATION WITH FOCUS ON CB-010 AND CB-011 ONCOLOGY PROGRAMS CARIBOU BIOSCIENCES INC - TO REDUCE WORKFORCE BY 32% CARIBOU BIOSCIENCES INC - DISCONTINUES GALLOP PHASE 1 TRIAL OF CB-010 FOR LUPUS CARIBOU BIOSCIENCES INC - DISCONTINUES AMPLIFY PHASE 1 TRIAL OF CB-012 FOR AML CARIBOU BIOSCIENCES INC - CHANGES EXPECTED TO EXTEND CASH RUNWAY INTO H2 2027 CARIBOU BIOSCIENCES INC - TO PRESENT DATA FROM CB-010 AND CB-011 IN H2 2025 Source text: ID:nGNXbzM3y0 Further company coverage: CRBU.O ((Reuters.Briefs@thomsonreuters.com))